Characterization of BRCA Deficiency in Ovarian Cancer
, Claudio Ceccarelli 2, Lea Godino 1, Sara Miccoli 1, Simona Ferrari 1, Donatella Santini 1, Pierandrea De Iaco 1,2, Claudio Zamagni 1, Giovanni Innella 1,2,* and Daniela Turchetti 1,2Round 1
Reviewer 1 Report
It is a good paper with implications in clinical practice
Author Response
We thank reviewer 1 for appreciating our work. We have tried to further improve the paper trying to satisfy the comments of the other reviewers, adjusting the "Simple summary" and "Abstract" parts and adding the "Conclusions" paragraph.
Reviewer 2 Report
I appreciate the opportunity to review this manuscript I looked forward to learning significantly from conclusions, as this is a very active area of research.
I recommend publication of this manuscript
Author Response
We thank reviewer 2 for appreciating our work. We have tried to further improve the paper trying to satisfy the comments of the other reviewers, adjusting the "Simple summary" and "Abstract" parts and adding the "Conclusions" paragraph.
Reviewer 3 Report
Table 5: It is recommended that authors add a row, detailing the intensity of adjuvant treatment with taxanes and platinum in both groups, since this may be the most important factor that could influence PFS and OS.
Author Response
We thank reviewer 3 for reviewing our paper. As suggested, we have added in Table 5 a row detailing the intensity of adjuvant treatment with taxanes and platinum in both groups. Furthermore, we have tried to further improve the paper adjusting the "Simple summary" and "Abstract" parts and adding the "Conclusions" paragraph.
